Adenoid cystic carcinoma of trachea

CT-guided palladium-103 seed brachytherapy for metastatic adenoid cystic carcinoma: a retrospective study to assess initial safety and effectiveness of percutaneous CT fluoroscopy-guided permanent seed brachytherapy

“…The 5-and 15-year survival rates for ACC are approximately 89% and 40%, respectively [16]. Metastasectomy is a frequently reported treatment option for patients with various pulmonary metastases; although, patients with insufficient pulmonary reserve may not qualify for surgical intervention [3,[17][18][19]. Radio-frequency ablation, microwave ablation, and cryotherapy ablation are competing technologies for the treatment of lung neoplasms, with a 0-34% of local recurrence rate and a pneumothorax rate of 25-39% [15,18,20,21].…”

“…ACC appears to spread by hematogenous, perineural, and lymphatic routes. However, the hematogenous route predominates in many cases, and metastases to lung, liver, bone, and brain can be observed after long periods of indolence [3]. Approximately half of all patients presenting with ACC will develop metastatic disease or succumb to local recurrence [2].…”

Primary adenoid cystic carcinoma of the trachea: a report of two cases and literature review

“…The incidence of tracheal tumors is less than 0,2 per 100,000 people per year [ 1 ]; only 10% of these cases are ACC [ 8 ]. ACCs have been reported without sex predilection in patients in the fifth decade of life; our patients are 49 and 50 years old; and smoking does not affect the incidence of ACC [ 9 ]. Patients with ACC usually present with symptoms such as coughing, wheezing and dyspnea and are often treated for asthma for months to years before being correctly diagnosed [ 1 ], as our second patient.…”

“…More than 50% of patients with tracheal ACC have hematogenous metastases. Pulmonary metastases are the most commun and can remain asymptomatic for many years [ 9 ]. Metastases to the brain, bone, liver, kidney, skin, abdomen; and heart have also been reported [ 1 , 2 , 5 ].…”

“…On CT, the tumor infiltration in the submucosa manifests as an intraluminal mass of soft-tissue attenuation with extension through the tracheal wall, and a diffuse or circumferential wall thickening of the trachea, a soft-tissue mass filling the airway, or a homogeneous mass encircling the trachea with wall thickening in the transverse and longitudinal planes [ 2 ]. MRI because of its multiplanarity and better tissue characterization can better define the extent of the submucosal infiltration, and local mediastinal invasion than CT that may influence resectability [ 9 ].…”